智通财经APP获悉，康诺亚-B(02162)再涨超6%，截至发稿，涨5.9%，报43.05港元，成交额8054.96万港元。
消息面上，康诺亚发布年度业绩，收入4.28亿元人民币，同比增长21%；母公司拥有人应占亏损5.15亿元，同比扩大43.4%。华泰证券指出，司普奇拜单抗在2024年底获批后三个半月销售额约4300万元，商业化起步表现强劲。
浦银国际指出，公司2024年收入和净亏损均好于预期.展望未来，管理层维持此前披露的2025年CM310销售收入5亿元指引及之前所述的长期销售峰值目标50亿元。CM310头两个适应症有望于2025年下半年参加医保谈判及于2026年纳入医保，届时销售将进一步加速增长。适应症拓展方面，青少年AD有望于1H25申报上市，结节性痒疹或有望于2H25申报上市。其他资产研发推进顺利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.